MedTrace Logo

CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial

NCT05360290 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 484

Last updated 2026-02-03

No results posted yet for this study

Summary

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.

Conditions

Interventions

DEVICE

GILUPI CellCollector®

Use of GILUPI CellCollector® to detect CTC

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2026-06-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360290 on ClinicalTrials.gov